She obtained her Ph.D. in Pharmacology from King's College, London in 1981, and since then the primary focus of her work has been cardiomyocyte function in the failing heart. This has extended to gene therapy to modulate cardiomyocyte function, and she is Scientific PI for the UK's first clinical trial on myocardial gene therapy. More recently the scope has extended to the characterisation of cardiomyocytes derived from embryonic stem cells, and their use in cardiac repair, tissue engineering and drug discovery.
Professor Harding is Past-President of the European Section of the International Society for Heart Research and Fellow of the AHA, ESC and ISHR. She sits on the Nuffield Council on Bioethics and the Scientific Advisory Board of the PPP "Stem Cells for Safer Medicines".
Professor Harding delivered her Inaugural Lecture, entitled 'Reviving the Failing Heart: one cell at a time', on 3 April 2007. The abstract and other details of the lecture can be found here.
et al., 2018, Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition., Cardiovasc Res
et al., 2018, Auxetic Cardiac Patches with Tunable Mechanical and Conductive Properties toward Treating Myocardial Infarction, Advanced Functional Materials, Vol:28, ISSN:1616-301X
et al., 2018, Cardiomyocyte Membrane Structure and cAMP Compartmentation Produce Anatomical Variation in beta(2)AR-cAMP Responsiveness in Murine Hearts, Cell Reports, Vol:23, ISSN:2211-1247, Pages:459-469
et al., Structural and functional plasticity of myocardial slices in response to prolonged mechanical loading and unloading in vitro, European Society of Cardiology Congress 2017
et al., 2018, STAT3 mediates differentiation and maintenance of human pluripotent stem-derived endothelial cells, 5th Congress of the ESC-Council-on-Basic-Cardiovascular-Science on Frontiers in Cardio Vascular Biology, OXFORD UNIV PRESS, Pages:S39-S39, ISSN:0008-6363